The DOI matches its Crossref record; 229 of the 229 references it cites were found in a registry or an index.
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Open accessAbstract
Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling mediates almost all immune regulatory processes, including those that are involved in tumor cell recognition and tumor-driven immune escape. Antitumor immune responses are largely driven by STAT1 and STAT2 induction of type I and II interferons (IFNs) and the downstream programs IFNs potentiate. Conversely, STAT3 has been widely linked to cancer cell survival, immunosuppression, and sustained inflammation in the tumor microenvironment. The discovery of JAK-STAT cross-regulatory mechanisms, post-translational control, and non-canonical signal transduction has added a new level of complexity to JAK-STAT governance over tumor initiation and progression. Endeavors to better understand the vast effects of JAK-STAT signaling on antitumor immunity have unearthed a wide range of targets, including oncogenes, miRNAs, and other co-regulatory factors, which direct specific phenotypical outcomes subsequent to JAK-STAT stimulation. Yet, the rapidly expanding field of therapeutic developments aimed to resolve JAK-STAT aberrations commonly reported in a multitude of cancers has been marred by off-target effects. Here, we discuss JAK-STAT biology in the context of immunity and cancer, the consequences of pathway perturbations and current therapeutic interventions, to provide insight and consideration for future targeting innovations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–229 of 229
STAT5 Contributes to Interferon Resistance of Melanoma Cells
Wellbrock, C., Weisser, C., Hassel, J. C., Fischer, P., Becker, J. C., Vetter, C. S., Behrmann, I., Kortylewski, M., Heinrich, P. C., & Schartl, M. (2005) · Current Biology · doi:10.1016/j.cub.2005.08.036 · Cited by 72
Yoshikawa, T., Takata, A., Otsuka, M., Kishikawa, T., Kojima, K., Yoshida, H., & Koike, K. (2012) · Scientific Reports · doi:10.1038/srep00637 · Cited by 72
Thaker, Y. R., Schneider, H., & Rudd, C. E. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.10.020 · Cited by 69
Kim, H. S., Kim, D. C., Kim, H.-M., Kwon, H., Kwon, S. J., Kang, S., Kim, S. C., & Choi, G.-E. (2015) · Scientific Reports · doi:10.1038/srep13414 · Cited by 68
Siltuximab (CNTO 328): a promising option for human malignancies
Chen, B.-A., & Chen, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86438 · Cited by 65
Putz, E. M., Guillerey, C., Kos, K., Stannard, K. A., Miles, K. M., Delconte, R. B., Takeda, K., Nicholson, S. E., Huntington, N. D., & Smyth, M. J. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1267892 · Cited by 65
Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer
Sharma, J., & Larkin, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00324 · Cited by 65
Yöyen-Ermiş, D., Tunalı, G., Tavukçuoğlu, E., Horzum, U., Özkazanç, D., Sütlü, T., Büyükaşık, Y., & Esendağlı, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-48256-4 · Cited by 65
JAKs go nuclear: Emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth
Zouein, F. A., Duhé, R. J., & Booz, G. W. (2011) · Growth Factors · doi:10.3109/08977194.2011.614949 · Cited by 64
Li, S. D., Ma, M., Li, H., Waluszko, A., Sidorenko, T., Schadt, E. E., Zhang, D. Y., Chen, R., & Ye, F. (2017) · Genome Medicine · doi:10.1186/s13073-017-0478-1 · Cited by 62
IFN-gamma Induction of p21WAF1 Is Required for Cell Cycle Inhibition and Suppression of Apoptosis
Hobeika, A. C., Etienne, W., Torres, B. A., Johnson, H. M., & Subramaniam, P. S. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099312812 · Cited by 59
Stewart, M., Choi, Y., Johnson, G., Yu-Lee, L., Bazer, F., & Spencer, T. E. (2002) · Biology of Reproduction · doi:10.1095/biolreprod66.2.393 · Cited by 59
MiR-629 promotes human pancreatic cancer progression by targeting FOXO3
Yan, H., Li, Q., Wu, J., Hu, W., Jiang, J., Shi, L., Yang, X., Zhu, D., Ji, M., & Wu, C. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.525 · Cited by 59
Boudreau, J. E., Stephenson, K. B., Wang, F., Ashkar, A. A., Mossman, K. L., Lenz, L. L., Rosenthal, K. L., Bramson, J. L., Lichty, B. D., & Wan, Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3025 · Cited by 57
BRCA1 Regulates IFN-γ Signaling through a Mechanism Involving the Type I IFNs
Buckley, N. E., Hosey, A. M., Gorski, J. J., Purcell, J. W., Mulligan, J. M., Harkin, D. P., & Mullan, P. B. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0250 · Cited by 53
Beyond the histone tale: HP1α deregulation in breast cancer epigenetics
Vad‐Nielsen, J., & Nielsen, A. L. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2014.1001277 · Cited by 49
Puhr, M., Hoefer, J., Eigentler, A., Dietrich, D., van Leenders, G., Uhl, B., Hoogland, M., Handle, F., Schlick, B., Neuwirt, H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.292 · Cited by 48
Schroder, K., Spille, M., Pilz, A., Lattin, J. E., Bode, K. A., Irvine, K. M., Burrows, A. D., Ravasi, T., Weighardt, H., Stacey, K. J., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3495 · Cited by 48
Pillars Article: M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J. Immunol. 2000. 164: 6166–6173
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701141 · Cited by 48
Yao, K., Chen, Q., Wu, Y., Liu, F., Chen, X., & Zhang, Y. (2017) · Journal of Cell Science · doi:10.1242/jcs.200659 · Cited by 44
Cornez, I., Yajnanarayana, S. P., Wolf, A. M., & Wolf, D. G. F. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.035 · Cited by 43
Wang, Q., Shen, S., Sun, H.-W., Xing, Z.-X., & Yang, H.-L. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.118 · Cited by 43
Jaks, Stats and the Immune System
Decker, T., & Meinke, A. L. (1997) · Immunobiology · doi:10.1016/s0171-2985(97)80031-9 · Cited by 39
Vitale, M., Bassini, A., Secchiero, P., Mirandola, P., Ponti, C., Zamai, L., Mariani, A. R., Falconi, M., & Azzali, G. (2002) · The Anatomical Record · doi:10.1002/ar.10039 · Cited by 37
Cytokine regulation of expression of class I MHC antigens
Raval, A., Puri, N., Rath, P. C., & Saxena, R. K. (1998) · Experimental & Molecular Medicine · doi:10.1038/emm.1998.1 · Cited by 35
Seegert, D., Strehlow, I., Klose, B., Levy, D. E., Schindler, C., & Decker, T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37235-6 · Cited by 32
Interleukin-15: New kid on the block for antitumor combination therapy
den Bergh, J. M. J. V., Tendeloo, V. F. V., & Smits, E. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.09.001 · Cited by 31
Reduced Risk of Bone Metastasis for Patients With Breast Cancer Who Use COX-2 Inhibitors
Valsecchi, M. E., Pomerantz, S. C., Jaslow, R. J., & Tester, W. J. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.038 · Cited by 28
Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis
Park, J., Kim, J., Park, B.-R., Yang, K., Sun, E. J., Tognon, C. E., Sorensen, P. H. B., & Kim, S. (2018) · Oncogene · doi:10.1038/s41388-017-0102-2 · Cited by 14
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Adipose tissue and insulin resistance in obese
Ahmed, B., Sultana, R., & Greene, M. W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111315 · Cited by 1,047
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Wang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 569
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Metadata
- Authors
- Owen, K. L., Brockwell, N. K., & Parker, B. S.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-12-12
- Volume
- 11
- Issue
- 12
- Pages
- 2002
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2996238888
- Cited by
- 714
- References
- 229
- FWCI
- 25.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.